On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption DehydraTECH presents numerous opportunities and has been evaluated in … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs”

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats

Lexaria Bioscience Corp. (NASDAQ: LEXX), an innovator of drug delivery methods, is improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs with its patented technology. “DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro and human clinical testing,” reads a recent article. … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats”

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD”

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery

One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion  Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments Since its inception, … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery”

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of proprietary patented drug-delivery platform DehydraTECH(TM), recently released partial results from human clinical study HYPER-H21-1. The study evaluated DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension/high blood pressure. “The partial results showed that blood pressure was reduced across both male and female volunteers; it was more pronounced … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD

Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD”

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment

Related Editorial Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That’s a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, … Continue reading “NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its CEO and Chairman Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The event is slated to take place virtually from Sept. 13-15, 2021. According to the update, Bunka will provide an overview of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Present at H.C. Wainwright 23rd Annual Global Investment Conference”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217